Evidence map›Paper›PMID 36661492›Full record

ReviewCurrent issues in molecular biology2022

Liver Damage and microRNAs: An Update.

Erika Cione, Diana Marisol Abrego Guandique, Maria Cristina Caroleo, Filippo Luciani, Manuela Colosimo, Roberto Cannataro

Open access · goldAbstract readReview
In one paragraph

Review in Current issues in molecular biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. HBV/HCV coinfection and anti-tuberculosis drug-induced liver injury: from risk assessment and exploration of mechanisms to preventive considerations.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  4. Acetaminophen-induced acute liver injury abrogates the cytosine methylation pathway.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Erika CioneDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.ORCID 0000-0002-0562-0597
Diana Marisol Abrego GuandiqueGalascreen Laboratories, University of Calabria, 87036 Rende, Italy.
Maria Cristina CaroleoGalascreen Laboratories, University of Calabria, 87036 Rende, Italy.
Filippo LucianiInfectious Disease Unit Annunziata Hospital, 87100 Cosenza, Italy.
Manuela ColosimoMicrobiology Unit Pugliese Ciaccio Hospital, 88100 Catanzaro, Italy.
Roberto CannataroDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.ORCID 0000-0002-1668-7690
Magna Graecia University · ITUniversity of Calabria · ITAzienda Ospedaliera Pugliese Ciaccio · ITOspedale Annunziata di Cosenza · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the major organs in the body with multiple functions is the liver. It plays a central role in the transformation of macronutrients and clearance of chemicals and drugs. The serum biomarkers often used to indicate liver damage are not specifically for drug-induced liver injury (DILI) or liver injury caused by other xenobiotics, nor for viral infection. In this case, microRNAs (miRNAs) could play an exciting role as biomarkers of specific liver damage. In this review, we aimed to update the current literature on liver damage induced by drugs, as acute conditions and viral infections mediated by the hepatitis B virus (HBV) linked these two conditions to advanced research, with a focus on microRNAs as early biomarkers for liver damage. The undoubtable evidence that circulating miR-122 could be used as a human biomarker of DILI came from several studies in which a strong increase of it was linked with the status of liver function. In infancy, there is the possibility of an early miRNA detection for hepatitis B virus infection, but there are a lack of solid models for studying the HVB molecular mechanism of infection in detail, even if miRNAs do hold unrealized potential as biomarkers for early detection of hepatitis B virus infection mediated by HBV.

Indexed as

drug-induced liver injuryearly biomarkershepatitis B virus infectionmicroRNAs

Identifiers

PMID36661492
PMCPMC9857663
OpenAlexW4312205641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.